Statement on Cannabis Oils and Derivatives
July 8, 2015 /CNW/ - CanniMed Ltd. congratulates Health Canada on their proactive move today by announcing the Section 56 Class Exemption for Licensed Producers as a result of the recent Supreme Court decision regarding cannabis preparations and derivatives.
"We support the new regulations as being a very reasonable way to approach the safe and effective development of oils and alternate preparations of cannabis," said Brent Zettl, President and CEO of CanniMed Ltd. "Patient requests for products have been significant and we are pleased that Health Canada has recognized the need to modify the Marihuana for Medical Purposes Regulations (MMPR)."
Research and development into oils and alternate preparations of all of the CanniMed products is already well underway. The operating procedures and facilities are in place to comply with this next phase in the corporate business model.
No issues are expected with bringing manufacturing and product packaging into compliance with today's new licensing requirements as announced by Health Canada. CanniMed will make these products available to patients as soon as possible.
About CanniMed and Prairie Plant Systems
CanniMed Ltd. was the first producer to be licensed under the new Marihuana for Medical Purposes Regulations (MMPR). Our pharmaceutical-grade marijuana is produced under Good Manufacturing Practices (GMP) regulations, the criteria used to manufacture all pharmaceuticals in Canada. Our primary focus is on patient safety, undertaken by strictly following a 281 point quality control process.
CanniMed's parent company, Prairie Plant Systems Inc. was the sole supplier to Health Canada under the former medical marijuana system for 13 years, and has been producing safe and consistent medical marijuana for thousands of Canadian patients, with no incident of diversion.
These two companies together have created the leading medical cannabis company in Canada with a strong corporate priority to design and execute clinical research that will close the gap between the anecdotal benefit and evidence based medicine in order to standardize care. Our Canadian-grown cannabis is already leading the way in standardizing care and has been used in a published clinical trial demonstrating the efficacy of smoked cannabis for chronic pain,i which was used in the development of the Canadian Pain Society's Pharmacological management of chronic neuropathic pain: Revised consensus statement positioning medical cannabis as third line treatment for neuropathic pain.ii
i Ware, M.A., Wang, T., Shapiro, S., Robinson, A. and others. (2010) Smoked Cannabis for Chronic Pain: a Randomized Controlled Trial. Canadian Medical Association Journal (CMAJ). 182:E694-E701.
ii Moulin, D.E., Boulanger, A., Clark A.J., Dao, T. and others. (2014) Pharmacological Management of Chronic Neuropathic Pain: Revised Consensus Statement from the Canadian Pain Society. Pain Research and Management. Nov-Dec; 19(6): 328–335.
SOURCE CanniMed Ltd.
For further information:
Dara Willis Communications